Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor

Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor

Background: Elexacaftor-tezacaftor-ivacaftor (ETI) became available for adults with cystic fibrosis (CF) in 2019, but its impact on CF-related diabetes (CFRD) remains unclear. Methods: A single-center retrospective cohort study was conducted among adults with CFRD to examine the change in insulin do...

Full description

Saved in:
Bibliographic Details
Main Authors: Espérie Burnet, Deborah Grunewald, Etienne Larger, Florence Camus-Bablon, Catherine Eisenhauer, François Mifsud, Clémence Martin, Isabelle Honoré, Reem Kanaan, Nicolas Carlier, Johanna Fesenbeckh, Helen Mosnier-Pudar, Pierre-Régis Burgel
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Journal of Clinical & Translational Endocrinology
Subjects:
Cystic fibrosis related diabetes
Cystic fibrosis
Diabetes
Elexacaftor-tezacaftor-ivacaftor
Insulin dose adjusted hemoglobin A1c
Glycemic control
Online Access:http://www.sciencedirect.com/science/article/pii/S2214623725000250
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2214623725000250

Similar Items